SYNERGY™ XD

Everolimus-Eluting Platinum Chromium Coronary Stent System

play icon
Introducing SYNERGY™ XD
The SYNERGY™ XD BP Stent
FIRST and ONLY 48 mm DES in the U.S.
Indicated for use in High Bleeding Risk patients*
synchronous drug elution and polymer absorption
play icon
Introducing SYNERGY™ XD
The SYNERGY™ XD BP Stent
FIRST and ONLY 48 mm DES in the U.S.
Indicated for use in High Bleeding Risk patients*
synchronous drug elution and polymer absorption
Introducing SYNERGY™ XD
The SYNERGY™ XD BP Stent features an innovative delivery system for Xtra Deliverability.
Size matrix includes the FIRST and ONLY 48 mm DES in the U.S.
Indicated for use in High Bleeding Risk patients*
Unlike permanent polymer DES technology, the SYNERGY™ XD BP Stent features synchronous drug elution and polymer absorption for optimal healing.

Delivering More.

Xtra Deliverability. Optimal Healing.

Introducing the next generation SYNERGY™ Bioabsorbable Polymer (BP) Stent. The SYNERGY™ XD Stent System is equipped with a delivery system designed to make optimal healing even more deliverable.

Explore

 

Visibility

 

Why Visibility is Important

Good visualization is key for accurate placement and optimal outcomes. Stent misplacement at the ostium occurs frequently and is associated with higher rates of restenosis and target lesion revascularization (TLR).*

SYNERGY Visibility Pie Chart
True ostium was missed in 54% of cases.*
 

See the difference

Even with thin struts, the high density of Platinum Chromium allows for greater visibility.†

 
SYNERGY Visibility Chart
 

* “High Incidence of Inaccurate Stent Placement in the Treatment of Coronary Aorto-Ostial disease” : https://www.invasivecardiology.com/articles/high-incidence-inaccurate-stent-placement-treatment-coronary-aorto-ostial-disease
† Testing Completed by Boston Scientific data on file. 2.5 mm stent products tested. Based on 2.5mm stents. Under 6.0mm copper phantom to simulate body mass. Bench test results may not necessarily be indicative of clinical performance.

 

Xtra Deliverability

 

Innovative Delivery System

The SYNERGY™ XD BP Stent System combines added trackability and pushability with a low-profile stent platform to enable better navigation of challenging anatomy.‡

 
Xtra Deliverability

‡ Based on bench testing of SYNERGY™ and SYNERGY™ XD BP Stents. Radial Guide Tracking and Radial Push Transmission; 3.00 mm stent systems tested, n=15 units. Bench testing performed by Boston Scientific. Results not necessarily indicative of clinical performance.

 

SYNERGY™ XD 48 mm

 

Designed for Complex Cases

  • Excellent Conformability
  • Exceptional Overexpansion up to 5.75 mm§

    •  

Procedural Efficiency

  • Reduced Treatment Cost
  • Reduced Procedure Time
  • Reduced Radiation Exposure and Contrast1
 

Quality Outcomes for Patients

1-year results from the EVOLVE 48 Trial support the safety and effectiveness of the SYNERGY™ XD 48 mm BP Stent for the treatment of long lesions**2

Learn More
Quality Outcomes for Patients, SYNERGY XD product shot

§ The labeled dilation limit of the 4.00 - 5.00 mm stent diameters is 5.75 mm. Please see the SYNERGY™ XD DFU for dilation limits for all diameters.
** Clinical data conducted with SYNERGY™ 48 mm, SYNERGY™ XD’s predecessor device, which can be used to illustrate SYNERGY™ XD 48 mm clinical data.

 

Studying DAPT

Indicated for Use in High Bleeding Risk Patients††

The SYNERGY™ BP Stent can be safely used in conjunction with shortened DAPT in patients at high risk for bleeding (HBR), based on the results from the EVOLVE Short DAPT Trial. This trial data in conjunction with the HBR indication, provides important evidence to inform decisions about DAPT duration for this patient subset.

 


HIGH BLEEDING RISK INDICATION, SYNERGY XD Stent

EVOLVE Short DAPT Trial ‡‡³

Studying 3-month DAPT in high bleeding risk patients
 

†† in the US. The HBR indication excludes the SYNERGY™ XD 48 mm stent.
‡‡ EVOLVE Short DAPT is a prospective, multicenter, single-arm trial defining the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with the SYNERGY™ BP Stent. Approximately 74% of patients enrolled discontinued DAPT at 3-months. N=1,396 (patients with respective event or sufficient follow-up). Co-primary endpoints: ARC Def/Prob ST and Death/MI from 3-15 months. High risk bleeding subjects were defined as meeting one or more of the following criteria: ≥75 years of age and, in the opinion of the investigator, the risk of bleeding associated with >3 months of DAPT outweighs the benefit; need for chronic or lifelong anticoagulation, history of major bleeding (severe/ life threatening or moderate bleeding based on the GUSTO classification) within 12 months of the index procedure; history of stroke (ischemic or hemorrhagic); renal insufficiency (creatinine ≥2.0 mg/dl) or failure (dialysis dependent); platelet count ≤100,000/μL.

 

Optimal Healing

Fast Absorbing Bioabsorbable Polymer Advantage

Unlike permanent polymer DES technology, the SYNERGY™ XD Bioabsorbable Polymer is gone shortly after the drug is completely eluted.4

Optimal Healing, SYNERGY XD

Trusted Everolimus Drug

Optimized drug elution to be synchronous with polymer absorption

 

Abluminal Polymer Application

Suppresses neointimal growth while promoting early healing

 

Thin, Rounded Struts

Stents with thinner struts heal faster than thicker stent struts5

 
 

Ordering Information

 

Stent Length (mm)

ø 

(mm)

81216202428323848

Expansion

Limit

2.25 H7493941708220H7493941712220H7493941716220H7493941720220H7493941724220H7493941728220H7493941732220H7493941738220 3.50
2.50 H7493941708250H7493941712250H7493941716250H7493941720250H7493941724250H7493941728250H7493941732250H7493941738250H74939417482503.50
2.75H7493941708270H7493941712270H7493941716270H7493941720270H7493941724270H7493941728270H7493941732270H7493941738270H74939417482703.50
3.00H7493941708300H7493941712300H7493941716300H7493941720300H7493941724300H7493941728300H7493941732300H7493941738300H74939417483004.25
3.50H7493941708350H7493941712350H7493941716350H7493941720350H7493941724350H7493941728350H7493941732350H7493941738350H74939417483504.25
4.00H7493941708400H7493941712400H7493941716400H7493941720400H7493941724400H7493941728400H7493941732400H7493941738400H74939417484005.75
4.50 H7493941712450H7493941716450H7493941720450H7493941724450H7493941728450H7493941732450  5.75
5.00 H7493941712500H7493941716500H7493941720500H7493941724500H7493941728500H7493941732500  5.75
 
 
Xtra Deliverability

Xtra Deliverability

Learn about the continued advancement in deliverability that SYNERGY™ XD offers

Button
SYNERGY™ XD 48 mm

SYNERGY™ XD 48 mm

Discover the First 48mm DES approved by US FDA

Button
Optimal Healing

Optimal Healing

Find out how synchronous drug elution and polymer absorption enables early healing

Button
 
 
 
Top